Aurinia Pharmaceuticals Inc. Cash And Cash Equivalents
Aurinia Pharmaceuticals Inc. (AUPH) had Cash And Cash Equivalents of $306.02 million as of 2019-12-31, per its 40-F filed 2020-03-05.
Discontinued › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
ifrs-full:CashAndCashEquivalents · last filed 2020-03-05
- 2019-12-31: Cash And Cash Equivalents $306.02M.
- 2018-12-31: Cash And Cash Equivalents $117.97M.
- 2017-12-31: Cash And Cash Equivalents $165.63M.
- 2016-12-31: Cash And Cash Equivalents $39.65M.
| Period end | Cash And Cash Equivalents |
|---|---|
| 2019-12-31 | $306.02M 40-F · filed 2020-03-05 |
| 2018-12-31 | $117.97M 40-F · filed 2020-03-05 |
| 2017-12-31 | $165.63M 40-F · filed 2020-03-05 |
| 2016-12-31 | $39.65M 40-F · filed 2019-03-19 |
| 2015-12-31 | $5.76M 40-F · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |